Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Entera Bio Ltd.NASDAQ: ENTX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables outflow grows to $0
Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $133.03K.
Context
- Accounts receivables amounted to 300.0% of revenue in FY2025, up 230.4 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $33.26K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 126K USD
- Year-over-year change
- +200.0%
- 4-year CAGR
- +15.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126K | +200.0% |
| FY2024 | 2024-12-31 | (126K) | -151.2% |
| FY2023 | 2023-12-31 | 246K | +490.5% |
| FY2022 | 2022-12-31 | (63K) | -187.5% |
| FY2021 | 2021-12-31 | 72K | — |
Accounts Receivables vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 accounts receivables of $133.03K is the 7th largest of the 10 companies compared; the peer median is $331.65K.
- Its year-over-year change of +205.6% is the 2nd highest of 8, against a peer median of -73.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.57M | -6016.2% | — | 5.3% | |
| LTM Mar 2026 | $2.53M | +162.9% | — | 220.4% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $2.04M | +224.6% | — | 17.0% |
| LTM Mar 2026 | $1.1M | +37.9% | — | 7.3% | |
| LTM Mar 2026 | $624K | -85.7% | +25.5% | 1.1% | |
| LTM Mar 2026 | $331.65K | -73.3% | — | — | |
| LTM Mar 2026 | $133.03K | +205.6% | — | — | |
| LTM Apr 2026 | $56K | -125.7% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ENTX) | $331.65K | -73.3% | +25.5% | 7.3% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| Deferred Income Tax | (217K) | 174K | 29K | 14K | 0 |
| Stock-Based Compensation | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M |
| Change in Working Capital | 1.41M | (1.84M) | (195K) | 112K | 1.26M |
| Accounts Receivables | 72K | (63K) | 246K | (126K) | 126K |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 74K | (149K) | 66K | 49K | 316K |
| Other Working Capital | 1.34M | (1.62M) | (507K) | 189K | 815K |
| Other Non-Cash Items | 18K | (78K) | 1.69M | (5K) | 32K |
| Operating Cash Flow | (9.06M) | (12.5M) | (7.31M) | (6.82M) | (7.37M) |
| Capital Expenditures | (17K) | (47K) | (17K) | (3K) | (107K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (55K) | 0 | 0 | 0 |
| Investing Cash Flow | (17K) | (102K) | (17K) | (3K) | (107K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 21.81M | 13K | 6.62M | 3.96M | 13.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.58M | 0 | (580K) | 516K | 0 |
| Financing Cash Flow | 25.38M | 13K | 6.04M | 4.48M | 13.71M |
| Effect of Forex Changes | 0 | 5K | 0 | 0 | (10K) |
| Net Change in Cash | 16.3M | (12.58M) | (1.29M) | (2.35M) | 6.23M |
| Free Cash Flow | (9.08M) | (12.55M) | (7.33M) | (6.82M) | (7.48M) |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.